Masson, Rahul
Jeong, Charlotte Y.
Ma, Elaine
Crew, Ashley B.
Fragoso, Natalie M.
Shi, Vivian Y.
Hsiao, Jennifer L.
Article History
Received: 23 June 2023
Accepted: 16 August 2023
First Online: 22 September 2023
Declarations
:
: Natalie M. Fragoso is an investigator for Acelyrin. Vivian Y. Shi is on the board of directors for the Hidradenitis Suppurativa Foundation (HSF), is an advisor for the National Eczema Association, is a stock shareholder of Learn Health, and has served as an advisory board member, investigator, speaker, and/or received research funding from Sanofi Genzyme, Regeneron, AbbVie, Genentech, Eli Lilly, Novartis, SUN Pharma, LEO Pharma, Pfizer, Incyte, Boehringer Ingelheim, Alumis Aristea Therapeutics, Menlo Therapeutics, Dermira, Burt’s Bees, Galderma, Kiniksa, UCB, Target-PharmaSolutions, Altus Lab/cQuell, MYOR, Polyfins Technology, GpSkin, and Skin Actives Scientific. Jennifer L. Hsiao is on the board of directors for the Hidradenitis Suppurativa Foundation, has served as a consultant for Aclaris, Boehringer Ingelheim, Novartis, and UCB, and has served as a consultant and speaker for AbbVie. Rahul Masson, Charlotte Y. Jeong, Elaine Ma, and Ashley B. Crew report no conflicts of interest.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.